Stocks · News reference

FDA Grants RMAT Designation To Ocugen’s Investigational Product OCU410 For Treatment Of Geographic Atrophy, Secondary To Dry Age-Related Macular Degeneration

Jul 29, 2026, 11:13 AMBenzinga Newsdesk

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaSep 1, 2026, 11:06 AMBenzinga Newsdesk
Ocugen Announces First Patient Dosed In Global Phase 3 Registrational Trial Of OCU410, Modifier Gene Therapy Candidate For GA Secondary To Dry Age-Related Macular Degeneration
The single global Phase 3 trial, ArMaDa3 (NCT07770828), is the first pivotal gene therapy trial in geographic atrophy (GA)U.S. Food and Drug Administration (FDA) granted OCU410 Regenerative Medicine Advanced Therapy
OCGN
SEC EDGARAug 6, 2026, 12:30 PMSEC EDGAR
8-K filing — Ocugen, Inc. (OCGN)
Filed: 2026-08-06 AccNo: 0001104659-26-091691 Size: 2 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
OCGN
BenzingaAug 6, 2026, 11:03 AMBenzinga Newsdesk
Ocugen Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $1.488M Beat $888.833K Estimate
Ocugen (NASDAQ:OCGN) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 40 percent decrease over losses of $(0.05) per share from the same
OCGN